Combination therapy for treating hypercholesterolemia
View Patent ↗The invention relates to methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal. The methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of a cholesterol-lowering agent. The first and second amounts together comprise a therapeutically effective amount. The invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol. The pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of a cholesterol-lowering agent. The first and second amounts comprise a therapeutically effective amount. The pharmaceutical compositions of the present invention may optionally contain a pharmaceutically acceptable carrier.
1. A pharmaceutical composition comprising a unit dosage form of a polydiallylamine homopolymer or a salt thereof, said homopolymer characterized by Formula I Formula II or a combination thereof:
and further characterized in that the polymer is free of alkylated amine monomers, and a pharmaceutically acceptable carrier, wherein said homopolymer is crosslinked by means of a multifunctional crosslinking agent, and said crosslinking agent is present in an amount from about 2.5-20% by weight, based upon the combined weight of monomer and crosslinking agent wherein the unit dosage form is a tablet.
2. The pharmaceutical composition of claim 1 wherein the polymer is crosslinked using epichlorohydrin.
3. A pharmaceutical composition comprising a unit dosage form of a polydiallylamine homopolymer or a salt thereof, said homopolymer characterized by Formula I, Formula II or a combination thereof:
and further characterized in that the polymer is free of alkylated amine monomers, and a pharmaceutically acceptable carrier, wherein said homopolymer is crosslinked by means of a multifunctional crosslinking agent, and said crosslinking agent is present in an amount from about 2.5-20% by weight, based upon the combined weight of monomer and crosslinking agent wherein the unit dosage form is a capsule.
4. The pharmaceutical composition of claim 1 , wherein the polydiallylamine homopolymer is in the free base form.
5. The pharmaceutical composition of claim 1 , wherein the polydiallylamine homopolymer is a salt or partial salt.
6. The pharmaceutical composition of claim 3 , wherein the polydiallylamine homopolymer is in the free base form.
7. The pharmaceutical composition of claim 3 , wherein the polydiallylamine homopolymer is a salt or partial salt.
8. The pharmaceutical composition of claim 3 , wherein the polymer is crosslinked using epichlorohydrin.
9. The pharmaceutical composition of claim 1 , wherein the polydiallylamine homopolymer is water-insoluble.
10. The pharmaceutical composition of claim 3 , wherein the polydiallylamine homopolymer is water-insoluble.